3 Stocks To Avoid For Your 2015 ISA: Barclays PLC, Lloyds Banking Group plc & AstraZeneca plc

Barclays PLC (LON:BAR), Lloyds Banking Group plc (LON:LLOY) and AstraZeneca plc (LON:AZN) are not the right investments for your ISA.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Barclays (LSE: BARC), Lloyds (LSE: LLOY) and AstraZeneca (LSE: AZN) should not be included in your ISA this year. Here’s why. 

Is A Reshuffle On The Cards At Barclays? 

The banking industry is still in recovery mode, but the shares of Barclays and Lloyds are not cheap enough to deserve attention, and there are more appealing dividend-paying shares in the marketplace, such as those of tobacco and consumer companies. Uncertainly surrounding the outlook for interest rates and shaky fundamentals also point to potential losses for these banks’ shares in the next year or so. 

Barclays has risen well beyond fair value since the end end of 2104, and its latest results showed that it’d take a miracle for the bank to deliver significant returns to shareholders in the near future. Its chief executive, Antony Jenkins, is adamant that Barclays will become a different, more responsible bank, but little evidence pointing to a decisive U-turn in the way business is carried out has been provided so far.

Its strategy and short-term prospects are not particularly appealing, either. In fact, I wouldn’t be surprised if shareholders decided to push for a change in management. 

Chief executive Antony Jenkins is one of 11 key executives to share a bumper payout, as the bank awaits a fine for its role in the forex rigging scandal,” The Guardian wrote in a recent article headed “Barclays risks shareholder backlash as managers share £16m share bonuses“.

This is one to watch. I’d consider Barclays only it traded 50p lower, or about 20% below its current level. 

Lloyds: Very Little Value In It

Lloyds is a terrible investment for your 2015 ISA, in my view. Every time I take a look at its share price, its equity valuation isn’t far away from 75p! How is that? 

As I argued last month, one of the biggest issues I have with Lloyds is that lots of Lloyds paper will flood the market over time, thus preventing the stock from rising. It’s very expensive, too, based the value of its tangible assets.  

Year to date, its performance reads 5%, as at the end of trade on March 20. In the last three months, its performance reads 5%. In the last six months, its performance reads 5%. Its one-year performance is almost 5%.

That’s a coincidence, of course, but it means a pretty simple thing: every time the government offloads a small portion of its stake — which is still significant at above 20% — the stock will go down, and then up again, slowly, until the next sale!

It’s going to be this way for a couple of years, in my view.

Moreover, such deals such as the sale of a large stake in TSB to Banco Sabadell will contribute to meaningful economic losses.

The transaction will lead to a charge through the group’s income statement of approximately £640 million reflecting the net costs of the transitional service agreement between Lloyds and TSB, the contribution to be provided by Lloyds to TSB in moving to alternative IT provision and the gain on sale,” Lloyds said, adding that the “capital impact upon settlement of the firm shares will be a c.21 bps decrease in the group’s common equity tier 1 capital ratio“.

While the bulls point to value as Lloyds remain a cheap alternative to riskier banking stock such as Barclays and Standard Chartered, I doubt the shares will appreciate in the next 12 months or so. 

AstraZeneca Is Too Expensive!

Expectations were high as recently as last week as AstraZeneca — my least favourite stock in the pharma universe — was meant to surprise the market with key findings about Brilinta. 

AstraZeneca spent four years and tested more than 20,000 patients trying to prove that the floundering cardiovascular pill Brilinta ought to be used long term after a heart attack. Those efforts have come to naught,” analysts at EP Vantage pointed out last week, adding that if Astra was expecting the anti-thrombotic pill to help lift sales of its currently marketed products to the heroic $45bn figure it forecast 10 months ago this result has dashed those hopes.

That’s pretty bad stuff, and I reckon that sales and earnings targets will have to come down at some point. 

In short, I think that the funds who wanted to get a top bid from Pfizer are still invested in the hope that someone will bail them out. But, based on Astra’s pipeline of drugs and limited growth potential, I truly believe that nobody should invest in it unless its stock drops to, say, £35. 

Shire and GlaxoSmithKline are much better alternatives. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended shares in GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »